Similar to its impact on BRCA-knockout cells, MED12 depletion promoted olaparib and cisplatin resistance in BRCA1-mutant MDA-MB-436 breast cancer cells and BRCA2-mutant PEO1 ovarian cancer cells (Figure 1G, Supplementary Figure S2). Here, MED12 is linked to breast cancer.